1. Home
  2. VIGL vs ORMP Comparison

VIGL vs ORMP Comparison

Compare VIGL & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIGL
  • ORMP
  • Stock Information
  • Founded
  • VIGL 2020
  • ORMP 2002
  • Country
  • VIGL United States
  • ORMP United States
  • Employees
  • VIGL N/A
  • ORMP N/A
  • Industry
  • VIGL Biotechnology: Pharmaceutical Preparations
  • ORMP Biotechnology: Pharmaceutical Preparations
  • Sector
  • VIGL Health Care
  • ORMP Health Care
  • Exchange
  • VIGL Nasdaq
  • ORMP Nasdaq
  • Market Cap
  • VIGL 89.3M
  • ORMP 90.7M
  • IPO Year
  • VIGL 2022
  • ORMP N/A
  • Fundamental
  • Price
  • VIGL $2.64
  • ORMP $2.17
  • Analyst Decision
  • VIGL Strong Buy
  • ORMP Hold
  • Analyst Count
  • VIGL 5
  • ORMP 1
  • Target Price
  • VIGL $21.00
  • ORMP N/A
  • AVG Volume (30 Days)
  • VIGL 2.6M
  • ORMP 113.6K
  • Earning Date
  • VIGL 03-25-2025
  • ORMP 03-05-2025
  • Dividend Yield
  • VIGL N/A
  • ORMP N/A
  • EPS Growth
  • VIGL N/A
  • ORMP N/A
  • EPS
  • VIGL N/A
  • ORMP 0.11
  • Revenue
  • VIGL N/A
  • ORMP N/A
  • Revenue This Year
  • VIGL N/A
  • ORMP N/A
  • Revenue Next Year
  • VIGL N/A
  • ORMP N/A
  • P/E Ratio
  • VIGL N/A
  • ORMP $20.19
  • Revenue Growth
  • VIGL N/A
  • ORMP N/A
  • 52 Week Low
  • VIGL $1.49
  • ORMP $2.00
  • 52 Week High
  • VIGL $6.06
  • ORMP $3.67
  • Technical
  • Relative Strength Index (RSI)
  • VIGL 71.47
  • ORMP 36.05
  • Support Level
  • VIGL $2.22
  • ORMP $2.12
  • Resistance Level
  • VIGL $2.53
  • ORMP $2.27
  • Average True Range (ATR)
  • VIGL 0.29
  • ORMP 0.07
  • MACD
  • VIGL 0.08
  • ORMP -0.01
  • Stochastic Oscillator
  • VIGL 80.47
  • ORMP 22.73

About VIGL Vigil Neuroscience Inc.

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.

About ORMP Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.

Share on Social Networks: